Dyne Therapeutics plans to submit its next-gen Duchenne muscular dystrophy drug to the FDA after a successful trial.

Dispersing federal research funding, largely concentrated at private universities on the coasts, to the rest of the country ...

Medical professionals should look past the partisan framing and engage with the substance of this debate,” write the authors ...

Some insurers have spent more on drugs in nine months this year than they did in all of 2024. Cost of weight loss drugs a ...

Dive deeper with STAT+. Gain unlimited access to expert analysis, newsletters, events, and news alerts.

In radiology, an early adopter of health AI, a debate is brewing: Should generative AI models interpret medical images on ...

At ASH 2025, Fulcrum presented promising data on a sickle cell pill and Incyte is pioneering a new way to treat myelofibrosis ...

Incyte's data bolster efforts to develop a new type of drug for myelofibrosis, and suggest it may be a replacement for Jakafi ...

A higher dose of the experimental pill for sickle cell disease showed more promise, Fulcrum said at the American Society of ...

Gilead and Arcellx reported promising data for their CAR-T therapy anito-cel at the annual American Society of Hematology ...